Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | BRS3 | P32247 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022718 | 0.81 | CTSS (0.50) | CTSSBRS3USP30CTSKIRAK4 | |
| SCHEMBL13750588 | 0.80 | CTSS (0.47) | CTSSBRS3USP30CTSKIDH1 | |
| SCHEMBL13728633 | 0.78 | CYP2A6 (0.51) | BRS3IRAK4TGFBR1 | |
| SCHEMBL13659740 | 0.77 | ASIC3 (0.49) | BRS3IDH1IRAK4TGFBR1 | |
| SCHEMBL13728687 | 0.77 | MAPT (0.45) | TGFBR1KDM5B | |
| SCHEMBL29310630 | 0.75 | BTK (0.42) | IDH1TGFBR1 | |
| SCHEMBL27446431 | 0.74 | KDM5B (0.40) | KDM5BPANK3 | |
| SCHEMBL13728929 | 0.73 | IDH1 (0.46) | IDH1TGFBR1 | |
| SCHEMBL179277 | 0.73 | HSD11B1 (0.41) | CTSSCTSKIDH1HSD11B1TGFBR1 | |
| SCHEMBL24345242 | 0.73 | CTSS (0.51) | CTSSBRS3CTSKIDH1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | CTSS 1941/4885BRS3 24/4885USP30 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.